Skip to main content

Proteomics International Inks Israeli Distribution Deal for Diabetic Kidney Disease Immunoassay

NEW YORK — Proteomics International said Thursday that it has signed a deal with Zotal to be the exclusive distributer of the immunoassay version of its PromarkerD diabetic kidney disease test in Israel.

The agreement is the first that Proteomics International has signed for PromarkerD in the Middle East and follows an Italian distribution agreement it announced in October.

The test measures the levels of protein in blood to detect the onset of kidney disease in type 2 diabetics. It is a high-throughput version of the Australian company's mass spectrometry-based PromarkerD (MS) test.

"The Israeli Ministry of Health attaches great importance to the prevention of diabetes by improving the monitoring of the disease," Dana Cohen, head of personalized and predictive medicine at Zotal, said in a statement. "The PromarkerD test could be a win-win for patients and the healthcare system and meaningful cost saving tool."

According to Proteomics International, diabetes is the fifth-leading cause of death in Israel and there are currently 550,000 people in Israel with the condition.

"We believe entering both the European and Middle Eastern markets in recent weeks will drive demand for PromarkerD in 2021 and beyond," said Richard Lipscombe, managing director of Perth, Australia-based Proteomics International, in a statement.

Financial and other terms of the agreement were not disclosed.